Stocks › CHRS
Coherus Oncology, Inc.
CHRS·Nasdaq·
United States·USD
United States·USD$1.03
-0.09 (-8.04%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
CHRS
Coherus Oncology, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CHRSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of CHRS by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Shri ThanedarHouse · D · MI |
CHRSCoherus Oncology, Inc. · Stock |
Sale $15,001 - $50,000 |
Feb 9, 2023 | Jan 23, 2023 | Filing ↗ |
Whale Activity
Position changes in CHRS reported for 2026-06-30 by 7 tracked institutional filers
- Increased4
- New0
- Held0
- Decreased3
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 12.0M | $16.8M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.9M | $8.3M | increased |
| TWO SIGMA INVESTMENTS, LP | 2.3M | $3.2M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 883.5K | $1.2M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 563.1K | $788K | increased |
| CITADEL ADVISORS LLC | 42.1K | $59K | decreased |
| MILLENNIUM MANAGEMENT LLC | 20.7K | $29K | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by CHRS insiders, by quarter · Form 4
Recent Insider Transactions
799 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Satvat Ali J.Director | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Karachun Rita ADirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Newcomer Lee NisleyDirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Ryan Michael LeeDirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| O'Donnell-Tormey JillDirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Wahlstrom MatsDirector | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Newton Charles W.Director | Grant / award | +30.0K | $0.00 | $0 | Jun 5, 2026 | Form 4 ↗ |
| Lanfear Dennis MPresident & CEO · Director | Grant / award | +375.0K | $0.00 | $0 | Jan 23, 2026 | Form 4 ↗ |
| McMichael Bryan JChief Financial Officer | Grant / award | +112.5K | $0.00 | $0 | Jan 22, 2026 | Form 4 ↗ |
| McMichael Bryan JChief Financial Officer | Tax withholding | −1,715 | $1.55 | $3K | Jan 20, 2026 | Form 4 ↗ |
| Lanfear Dennis MPresident & CEO · Director | Tax withholding | −11.8K | $1.55 | $18K | Jan 20, 2026 | Form 4 ↗ |
| Wahlstrom MatsDirector | Sale | −100.0K | $0.74 | $74K | May 23, 2025 | Form 4 ↗ |
| McMichael Bryan JChief Financial Officer | Tax withholding | −1,711 | $1.39 | $2K | Jan 20, 2025 | Form 4 ↗ |
| Reider PaulChief Commercial Officer | Tax withholding | −4,858 | $1.39 | $7K | Jan 20, 2025 | Form 4 ↗ |
| Lanfear Dennis MPresident & CEO · Director | Tax withholding | −11.8K | $1.39 | $16K | Jan 20, 2025 | Form 4 ↗ |
| McMichael Bryan JChief Financial Officer | Tax withholding | −1,711 | $1.57 | $3K | Jan 7, 2025 | Form 4 ↗ |
| Lanfear Dennis MPresident & CEO · Director | Tax withholding | −11.8K | $1.66 | $20K | Jan 4, 2025 | Form 4 ↗ |
| Reider PaulChief Commercial Officer | Tax withholding | −2,277 | $1.66 | $4K | Jan 4, 2025 | Form 4 ↗ |
| Reider PaulChief Commercial Officer | Tax withholding | −2,073 | $1.61 | $3K | Dec 13, 2024 | Form 4 ↗ |
| Wahlstrom MatsDirector | Gift | +100.0K | $0.00 | $0 | Feb 9, 2024 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding CHRS · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.0M | $5.5M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.2M | $4.5M | 0.01% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $2.6M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.4M | $2.0M | 0.01% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 927.8K | $1.5M | 0.03% | May 29, 2026 |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 900.0K | $1.3M | 0.17% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 783.2K | $1.2M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 709.1K | $1.1M | 0.00% | May 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 741.5K | $1.0M | 0.01% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 535.0K | $851K | 0.00% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list CHRS's shares (CUSIP 19249H103), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Coherus Oncology, Inc. as client
No lobbying filings found naming Coherus Oncology, Inc. as the client.
Government Contracts
Federal awards to Coherus Oncology, Inc. · USAspending
No federal contract awards found for Coherus Oncology, Inc..
U.S. Patents
Recent USPTO applications naming Coherus Oncology, Inc.
No USPTO patent applications found for Coherus Oncology, Inc..
Annual Financials
From CHRS's 10-K filings · XBRL
No annual XBRL figures on record for CHRS. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in CHRS's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 8.01, 9.01Other eventsAug 28, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsAug 17, 2026
EDGAR ↗ - 8-K · Items 1.01, 1.02, 2.03, 9.01Material agreement · Termination of agreement · Direct financial obligationAug 17, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 4.01, 9.01Change in auditorJun 15, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
EDGAR ↗
About Coherus Oncology, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersREDWOOD CITY, CA
IncorporatedDE
SEC CIK0001512762 ↗
Former namesCoherus BioSciences, Inc., BioGenerics, Inc.